



- | | |
|---|---|
| <p>(51) International Patent Classification:
 <i>A61K 31/4164</i> (2006.01) <i>A61P 35/00</i> (2006.01)</p> <p>(21) International Application Number:
 PCT/JP2022/008383</p> <p>(22) International Filing Date:
 28 February 2022 (28.02.2022)</p> <p>(25) Filing Language: English</p> <p>(26) Publication Language: English</p> <p>(30) Priority Data:
 63/154,426 26 February 2021 (26.02.2021) US
 63/222,323 15 July 2021 (15.07.2021) US</p> <p>(71) Applicant: ASTELLAS PHARMA INC., [JP/JP]; 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku Tokyo, 1038411 (JP).</p> <p>(72) Inventors: HAIRSTON John; c/o ASTELLAS US LLC 1 Astellas Way Northbrook, Illinois, 60062 (US). BROWN Bruce; c/o ASTELLAS US LLC 1 Astellas Way Northbrook, Illinois, 60062 (US).</p> | <p>(74) Agent: NAKAMURA Yukitaka et al.; Kyowa Patent & Law Office, Nippon Life Marunouchi Building, 1-6-6, Marunouchi, Chiyoda-ku, Tokyo, 1000005 (JP).</p> <p>(81) Designated States (<i>unless otherwise indicated, for every kind of national protection available</i>): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.</p> <p>(84) Designated States (<i>unless otherwise indicated, for every kind of regional protection available</i>): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,</p> |
|---|---|

(54) Title: METHODS OF REDUCING RISK OF PROSTATE CANCER PROGRESSION

[Fig. 1]



(57) Abstract: This disclosure provides methods of reducing the risk of prostate cancer progression in patients with a histologically proven prostate cancer characterized as low or intermediate risk for which no other treatment for prostate cancer is indicated. The method comprises administering enzalutamide as a monotherapy in an amount and for a period of time clinically proven effective in reducing the risk of prostate cancer progression in a control population of patients under active surveillance and having histologically proven prostate cancers characterized as low or intermediate risk for which no other treatment for prostate cancer is indicated.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))